Goldman Sachs Initiates United Therapeutics With Sell Rating
The bank started coverage of the pulmonary-disease drugmaker with a Sell while giving fellow gene-therapy name MeiraGTx a Neutral.
Goldman Sachs opened coverage on United Therapeutics with a Sell rating, a rare bearish call on a biotech that has built a lucrative franchise in pulmonary arterial hypertension drugs.
BREAKING STORYBEARISH